EC approves Sanofi’s Aubagio for paediatric MS patients
By Lucy Parsons The European Commission has approved Sanofi’s oral multiple sclerosis (MS) therapy Aubagio for the first-line treatment of…
Janssen’s Multiple Sclerosis Treatment Scores European Approval
The European Commission has approved Janssen’s, a unit of Johnson & Johnson Ponvory (ponesimod), to treat adult patients with relapsing multiple sclerosis.…
Stuart Schlossman
An MS medication in the Pipeline: UBLITUXIMAB (TG-1101) – A Novel Glycoengineered ANTI-CD20 Monoclonal Antibody
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to…
Stuart Schlossman
Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show
Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple…
Stuart Schlossman
EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
April 22, 2021 * New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute…
Stuart Schlossman
DIY drug infusion that halves the risk of relapse to benefit hundreds of thousands of multiple sclerosis patients
April 24, 2021 Monthly jab goes into the leg, arm or stomach using device similar to the EpiPen In trials,…
Stuart Schlossman
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
Published: Apr 15, 2021 TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent…
Stuart Schlossman
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of …
ROCKLAND, Mass.–(BUSINESS WIRE)–Apr 16, 2021– EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada,…
Stuart Schlossman
Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor Fenebrutinib
Fenebrutinib Phase III clinical trial programme Roche has an initiating a Phase III clinical trial programme for fenebrutinib, an investigational…
Stuart Schlossman
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…
Stuart Schlossman
